Aclaris Therapeutics Inc (NASDAQ:ACRS) – William Blair boosted their FY2018 earnings per share estimates for Aclaris Therapeutics in a note issued to investors on Monday. William Blair analyst T. Lugo now expects that the biotechnology company will earn ($3.85) per share for the year, up from their previous estimate of ($4.88). William Blair also issued estimates for Aclaris Therapeutics’ FY2019 earnings at ($2.87) EPS and FY2020 earnings at ($0.65) EPS.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.10. The business had revenue of $1.00 million during the quarter, compared to the consensus estimate of $0.80 million.
Aclaris Therapeutics (NASDAQ ACRS) traded up $0.03 during trading on Wednesday, reaching $19.89. 26,588 shares of the company’s stock traded hands, compared to its average volume of 331,792. The company has a market capitalization of $610.30, a P/E ratio of -8.24 and a beta of 1.45. Aclaris Therapeutics has a 1-year low of $18.46 and a 1-year high of $33.10.
Several hedge funds have recently added to or reduced their stakes in ACRS. Cubist Systematic Strategies LLC purchased a new stake in shares of Aclaris Therapeutics in the third quarter worth $142,000. Teacher Retirement System of Texas purchased a new position in shares of Aclaris Therapeutics in the 4th quarter worth approximately $200,000. MetLife Investment Advisors LLC purchased a new position in shares of Aclaris Therapeutics in the 4th quarter worth approximately $244,000. Trexquant Investment LP purchased a new position in shares of Aclaris Therapeutics in the 3rd quarter worth approximately $247,000. Finally, Voya Investment Management LLC purchased a new position in shares of Aclaris Therapeutics in the 2nd quarter worth approximately $247,000. Hedge funds and other institutional investors own 92.40% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.